Serveur d'exploration sur la rapamycine et les champignons

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Mitochondria-targeted drugs stimulate mitophagy and abrogate colon cancer cell proliferation.

Identifieur interne : 000548 ( Main/Exploration ); précédent : 000547; suivant : 000549

Mitochondria-targeted drugs stimulate mitophagy and abrogate colon cancer cell proliferation.

Auteurs : Kathleen A. Boyle [États-Unis] ; Jonathan Van Wickle ; R Blake Hill [États-Unis] ; Adriano Marchese [États-Unis] ; Balaraman Kalyanaraman [États-Unis] ; Michael B. Dwinell [États-Unis]

Source :

RBID : pubmed:30087121

Descripteurs français

English descriptors

Abstract

Mutations in the KRAS proto-oncogene are present in 50% of all colorectal cancers and are increasingly associated with chemotherapeutic resistance to frontline biologic drugs. Accumulating evidence indicates key roles for overactive KRAS mutations in the metabolic reprogramming from oxidative phosphorylation to aerobic glycolysis in cancer cells. Here, we sought to exploit the more negative membrane potential of cancer cell mitochondria as an untapped avenue for interfering with energy metabolism in KRAS variant-containing and KRAS WT colorectal cancer cells. Mitochondrial function, intracellular ATP levels, cellular uptake, energy sensor signaling, and functional effects on cancer cell proliferation were assayed. 3-Carboxyl proxyl nitroxide (Mito-CP) and Mito-Metformin, two mitochondria-targeted compounds, depleted intracellular ATP levels and persistently inhibited ATP-linked oxygen consumption in both KRAS WT and KRAS variant-containing colon cancer cells and had only limited effects on nontransformed intestinal epithelial cells. These anti-proliferative effects reflected the activation of AMP-activated protein kinase (AMPK) and the phosphorylation-mediated suppression of the mTOR target ribosomal protein S6 kinase B1 (RPS6KB1 or p70S6K). Moreover, Mito-CP and Mito-Metformin released Unc-51-like autophagy-activating kinase 1 (ULK1) from mTOR-mediated inhibition, affected mitochondrial morphology, and decreased mitochondrial membrane potential, all indicators of mitophagy. Pharmacological inhibition of the AMPK signaling cascade mitigated the anti-proliferative effects of Mito-CP and Mito-Metformin. This is the first demonstration that drugs selectively targeting mitochondria induce mitophagy in cancer cells. Targeting bioenergetic metabolism with mitochondria-targeted drugs to stimulate mitophagy provides an attractive approach for therapeutic intervention in KRAS WT and overactive mutant-expressing colon cancer.

DOI: 10.1074/jbc.RA117.001469
PubMed: 30087121
PubMed Central: PMC6153299


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Mitochondria-targeted drugs stimulate mitophagy and abrogate colon cancer cell proliferation.</title>
<author>
<name sortKey="Boyle, Kathleen A" sort="Boyle, Kathleen A" uniqKey="Boyle K" first="Kathleen A" last="Boyle">Kathleen A. Boyle</name>
<affiliation>
<nlm:affiliation>From the Department of Microbiology & Immunology.</nlm:affiliation>
<wicri:noCountry code="no comma">From the Department of Microbiology & Immunology.</wicri:noCountry>
</affiliation>
<affiliation wicri:level="2">
<nlm:affiliation>MCW Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Wisconsin</region>
</placeName>
<wicri:cityArea>MCW Cancer Center, Medical College of Wisconsin, Milwaukee</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Van Wickle, Jonathan" sort="Van Wickle, Jonathan" uniqKey="Van Wickle J" first="Jonathan" last="Van Wickle">Jonathan Van Wickle</name>
<affiliation>
<nlm:affiliation>From the Department of Microbiology & Immunology.</nlm:affiliation>
<wicri:noCountry code="no comma">From the Department of Microbiology & Immunology.</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Hill, R Blake" sort="Hill, R Blake" uniqKey="Hill R" first="R Blake" last="Hill">R Blake Hill</name>
<affiliation wicri:level="2">
<nlm:affiliation>MCW Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Wisconsin</region>
</placeName>
<wicri:cityArea>MCW Cancer Center, Medical College of Wisconsin, Milwaukee</wicri:cityArea>
</affiliation>
<affiliation>
<nlm:affiliation>Department of Biochemistry.</nlm:affiliation>
<wicri:noCountry code="no comma">Department of Biochemistry.</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Marchese, Adriano" sort="Marchese, Adriano" uniqKey="Marchese A" first="Adriano" last="Marchese">Adriano Marchese</name>
<affiliation wicri:level="2">
<nlm:affiliation>MCW Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Wisconsin</region>
</placeName>
<wicri:cityArea>MCW Cancer Center, Medical College of Wisconsin, Milwaukee</wicri:cityArea>
</affiliation>
<affiliation>
<nlm:affiliation>Department of Biochemistry.</nlm:affiliation>
<wicri:noCountry code="no comma">Department of Biochemistry.</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Kalyanaraman, Balaraman" sort="Kalyanaraman, Balaraman" uniqKey="Kalyanaraman B" first="Balaraman" last="Kalyanaraman">Balaraman Kalyanaraman</name>
<affiliation wicri:level="2">
<nlm:affiliation>MCW Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Wisconsin</region>
</placeName>
<wicri:cityArea>MCW Cancer Center, Medical College of Wisconsin, Milwaukee</wicri:cityArea>
</affiliation>
<affiliation>
<nlm:affiliation>Department of Biophysics.</nlm:affiliation>
<wicri:noCountry code="no comma">Department of Biophysics.</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Dwinell, Michael B" sort="Dwinell, Michael B" uniqKey="Dwinell M" first="Michael B" last="Dwinell">Michael B. Dwinell</name>
<affiliation wicri:level="1">
<nlm:affiliation>From the Department of Microbiology & Immunology, mdwinell@mcw.edu.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
<wicri:regionArea>From the Department of Microbiology & Immunology</wicri:regionArea>
</affiliation>
<affiliation wicri:level="2">
<nlm:affiliation>MCW Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Wisconsin</region>
</placeName>
<wicri:cityArea>MCW Cancer Center, Medical College of Wisconsin, Milwaukee</wicri:cityArea>
</affiliation>
<affiliation>
<nlm:affiliation>Department of Surgery, and.</nlm:affiliation>
<wicri:noCountry code="subField">and</wicri:noCountry>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:30087121</idno>
<idno type="pmid">30087121</idno>
<idno type="doi">10.1074/jbc.RA117.001469</idno>
<idno type="pmc">PMC6153299</idno>
<idno type="wicri:Area/Main/Corpus">000485</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000485</idno>
<idno type="wicri:Area/Main/Curation">000485</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000485</idno>
<idno type="wicri:Area/Main/Exploration">000485</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Mitochondria-targeted drugs stimulate mitophagy and abrogate colon cancer cell proliferation.</title>
<author>
<name sortKey="Boyle, Kathleen A" sort="Boyle, Kathleen A" uniqKey="Boyle K" first="Kathleen A" last="Boyle">Kathleen A. Boyle</name>
<affiliation>
<nlm:affiliation>From the Department of Microbiology & Immunology.</nlm:affiliation>
<wicri:noCountry code="no comma">From the Department of Microbiology & Immunology.</wicri:noCountry>
</affiliation>
<affiliation wicri:level="2">
<nlm:affiliation>MCW Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Wisconsin</region>
</placeName>
<wicri:cityArea>MCW Cancer Center, Medical College of Wisconsin, Milwaukee</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Van Wickle, Jonathan" sort="Van Wickle, Jonathan" uniqKey="Van Wickle J" first="Jonathan" last="Van Wickle">Jonathan Van Wickle</name>
<affiliation>
<nlm:affiliation>From the Department of Microbiology & Immunology.</nlm:affiliation>
<wicri:noCountry code="no comma">From the Department of Microbiology & Immunology.</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Hill, R Blake" sort="Hill, R Blake" uniqKey="Hill R" first="R Blake" last="Hill">R Blake Hill</name>
<affiliation wicri:level="2">
<nlm:affiliation>MCW Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Wisconsin</region>
</placeName>
<wicri:cityArea>MCW Cancer Center, Medical College of Wisconsin, Milwaukee</wicri:cityArea>
</affiliation>
<affiliation>
<nlm:affiliation>Department of Biochemistry.</nlm:affiliation>
<wicri:noCountry code="no comma">Department of Biochemistry.</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Marchese, Adriano" sort="Marchese, Adriano" uniqKey="Marchese A" first="Adriano" last="Marchese">Adriano Marchese</name>
<affiliation wicri:level="2">
<nlm:affiliation>MCW Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Wisconsin</region>
</placeName>
<wicri:cityArea>MCW Cancer Center, Medical College of Wisconsin, Milwaukee</wicri:cityArea>
</affiliation>
<affiliation>
<nlm:affiliation>Department of Biochemistry.</nlm:affiliation>
<wicri:noCountry code="no comma">Department of Biochemistry.</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Kalyanaraman, Balaraman" sort="Kalyanaraman, Balaraman" uniqKey="Kalyanaraman B" first="Balaraman" last="Kalyanaraman">Balaraman Kalyanaraman</name>
<affiliation wicri:level="2">
<nlm:affiliation>MCW Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Wisconsin</region>
</placeName>
<wicri:cityArea>MCW Cancer Center, Medical College of Wisconsin, Milwaukee</wicri:cityArea>
</affiliation>
<affiliation>
<nlm:affiliation>Department of Biophysics.</nlm:affiliation>
<wicri:noCountry code="no comma">Department of Biophysics.</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Dwinell, Michael B" sort="Dwinell, Michael B" uniqKey="Dwinell M" first="Michael B" last="Dwinell">Michael B. Dwinell</name>
<affiliation wicri:level="1">
<nlm:affiliation>From the Department of Microbiology & Immunology, mdwinell@mcw.edu.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
<wicri:regionArea>From the Department of Microbiology & Immunology</wicri:regionArea>
</affiliation>
<affiliation wicri:level="2">
<nlm:affiliation>MCW Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Wisconsin</region>
</placeName>
<wicri:cityArea>MCW Cancer Center, Medical College of Wisconsin, Milwaukee</wicri:cityArea>
</affiliation>
<affiliation>
<nlm:affiliation>Department of Surgery, and.</nlm:affiliation>
<wicri:noCountry code="subField">and</wicri:noCountry>
</affiliation>
</author>
</analytic>
<series>
<title level="j">The Journal of biological chemistry</title>
<idno type="eISSN">1083-351X</idno>
<imprint>
<date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adenosine Triphosphate (metabolism)</term>
<term>Adenylate Kinase (metabolism)</term>
<term>Autophagy-Related Protein-1 Homolog (metabolism)</term>
<term>Cell Line, Tumor (MeSH)</term>
<term>Cell Proliferation (drug effects)</term>
<term>Colonic Neoplasms (metabolism)</term>
<term>Colonic Neoplasms (pathology)</term>
<term>Energy Metabolism (MeSH)</term>
<term>Genes, ras (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Intracellular Signaling Peptides and Proteins (metabolism)</term>
<term>Mechanistic Target of Rapamycin Complex 1 (metabolism)</term>
<term>Membrane Potential, Mitochondrial (drug effects)</term>
<term>Mitochondria (drug effects)</term>
<term>Mitochondria (metabolism)</term>
<term>Mitophagy (drug effects)</term>
<term>Oxidative Phosphorylation (MeSH)</term>
<term>Signal Transduction (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Adenylate kinase (métabolisme)</term>
<term>Adénosine triphosphate (métabolisme)</term>
<term>Complexe-1 cible mécanistique de la rapamycine (métabolisme)</term>
<term>Gènes ras (MeSH)</term>
<term>Homologue de la protéine-1 associée à l'autophagie (métabolisme)</term>
<term>Humains (MeSH)</term>
<term>Lignée cellulaire tumorale (MeSH)</term>
<term>Mitochondries (effets des médicaments et des substances chimiques)</term>
<term>Mitochondries (métabolisme)</term>
<term>Métabolisme énergétique (MeSH)</term>
<term>Phosphorylation oxydative (MeSH)</term>
<term>Potentiel de membrane mitochondriale (effets des médicaments et des substances chimiques)</term>
<term>Prolifération cellulaire (effets des médicaments et des substances chimiques)</term>
<term>Protéines et peptides de signalisation intracellulaire (métabolisme)</term>
<term>Transduction du signal (effets des médicaments et des substances chimiques)</term>
<term>Tumeurs du côlon (anatomopathologie)</term>
<term>Tumeurs du côlon (métabolisme)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Adenosine Triphosphate</term>
<term>Adenylate Kinase</term>
<term>Autophagy-Related Protein-1 Homolog</term>
<term>Intracellular Signaling Peptides and Proteins</term>
<term>Mechanistic Target of Rapamycin Complex 1</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr">
<term>Tumeurs du côlon</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Cell Proliferation</term>
<term>Membrane Potential, Mitochondrial</term>
<term>Mitochondria</term>
<term>Mitophagy</term>
<term>Signal Transduction</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr">
<term>Mitochondries</term>
<term>Potentiel de membrane mitochondriale</term>
<term>Prolifération cellulaire</term>
<term>Transduction du signal</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Colonic Neoplasms</term>
<term>Mitochondria</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Adenylate kinase</term>
<term>Adénosine triphosphate</term>
<term>Complexe-1 cible mécanistique de la rapamycine</term>
<term>Homologue de la protéine-1 associée à l'autophagie</term>
<term>Mitochondries</term>
<term>Protéines et peptides de signalisation intracellulaire</term>
<term>Tumeurs du côlon</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Colonic Neoplasms</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Cell Line, Tumor</term>
<term>Energy Metabolism</term>
<term>Genes, ras</term>
<term>Humans</term>
<term>Oxidative Phosphorylation</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Gènes ras</term>
<term>Humains</term>
<term>Lignée cellulaire tumorale</term>
<term>Métabolisme énergétique</term>
<term>Phosphorylation oxydative</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Mutations in the KRAS proto-oncogene are present in 50% of all colorectal cancers and are increasingly associated with chemotherapeutic resistance to frontline biologic drugs. Accumulating evidence indicates key roles for overactive KRAS mutations in the metabolic reprogramming from oxidative phosphorylation to aerobic glycolysis in cancer cells. Here, we sought to exploit the more negative membrane potential of cancer cell mitochondria as an untapped avenue for interfering with energy metabolism in KRAS variant-containing and KRAS WT colorectal cancer cells. Mitochondrial function, intracellular ATP levels, cellular uptake, energy sensor signaling, and functional effects on cancer cell proliferation were assayed. 3-Carboxyl proxyl nitroxide (Mito-CP) and Mito-Metformin, two mitochondria-targeted compounds, depleted intracellular ATP levels and persistently inhibited ATP-linked oxygen consumption in both KRAS WT and KRAS variant-containing colon cancer cells and had only limited effects on nontransformed intestinal epithelial cells. These anti-proliferative effects reflected the activation of AMP-activated protein kinase (AMPK) and the phosphorylation-mediated suppression of the mTOR target ribosomal protein S6 kinase B1 (RPS6KB1 or p70S6K). Moreover, Mito-CP and Mito-Metformin released Unc-51-like autophagy-activating kinase 1 (ULK1) from mTOR-mediated inhibition, affected mitochondrial morphology, and decreased mitochondrial membrane potential, all indicators of mitophagy. Pharmacological inhibition of the AMPK signaling cascade mitigated the anti-proliferative effects of Mito-CP and Mito-Metformin. This is the first demonstration that drugs selectively targeting mitochondria induce mitophagy in cancer cells. Targeting bioenergetic metabolism with mitochondria-targeted drugs to stimulate mitophagy provides an attractive approach for therapeutic intervention in KRAS WT and overactive mutant-expressing colon cancer.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">30087121</PMID>
<DateCompleted>
<Year>2019</Year>
<Month>04</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised>
<Year>2019</Year>
<Month>12</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1083-351X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>293</Volume>
<Issue>38</Issue>
<PubDate>
<Year>2018</Year>
<Month>09</Month>
<Day>21</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of biological chemistry</Title>
<ISOAbbreviation>J Biol Chem</ISOAbbreviation>
</Journal>
<ArticleTitle>Mitochondria-targeted drugs stimulate mitophagy and abrogate colon cancer cell proliferation.</ArticleTitle>
<Pagination>
<MedlinePgn>14891-14904</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.RA117.001469</ELocationID>
<Abstract>
<AbstractText>Mutations in the KRAS proto-oncogene are present in 50% of all colorectal cancers and are increasingly associated with chemotherapeutic resistance to frontline biologic drugs. Accumulating evidence indicates key roles for overactive KRAS mutations in the metabolic reprogramming from oxidative phosphorylation to aerobic glycolysis in cancer cells. Here, we sought to exploit the more negative membrane potential of cancer cell mitochondria as an untapped avenue for interfering with energy metabolism in KRAS variant-containing and KRAS WT colorectal cancer cells. Mitochondrial function, intracellular ATP levels, cellular uptake, energy sensor signaling, and functional effects on cancer cell proliferation were assayed. 3-Carboxyl proxyl nitroxide (Mito-CP) and Mito-Metformin, two mitochondria-targeted compounds, depleted intracellular ATP levels and persistently inhibited ATP-linked oxygen consumption in both KRAS WT and KRAS variant-containing colon cancer cells and had only limited effects on nontransformed intestinal epithelial cells. These anti-proliferative effects reflected the activation of AMP-activated protein kinase (AMPK) and the phosphorylation-mediated suppression of the mTOR target ribosomal protein S6 kinase B1 (RPS6KB1 or p70S6K). Moreover, Mito-CP and Mito-Metformin released Unc-51-like autophagy-activating kinase 1 (ULK1) from mTOR-mediated inhibition, affected mitochondrial morphology, and decreased mitochondrial membrane potential, all indicators of mitophagy. Pharmacological inhibition of the AMPK signaling cascade mitigated the anti-proliferative effects of Mito-CP and Mito-Metformin. This is the first demonstration that drugs selectively targeting mitochondria induce mitophagy in cancer cells. Targeting bioenergetic metabolism with mitochondria-targeted drugs to stimulate mitophagy provides an attractive approach for therapeutic intervention in KRAS WT and overactive mutant-expressing colon cancer.</AbstractText>
<CopyrightInformation>© 2018 by The American Society for Biochemistry and Molecular Biology, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Boyle</LastName>
<ForeName>Kathleen A</ForeName>
<Initials>KA</Initials>
<AffiliationInfo>
<Affiliation>From the Department of Microbiology & Immunology.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>MCW Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Van Wickle</LastName>
<ForeName>Jonathan</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>From the Department of Microbiology & Immunology.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hill</LastName>
<ForeName>R Blake</ForeName>
<Initials>RB</Initials>
<AffiliationInfo>
<Affiliation>MCW Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Department of Biochemistry.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Marchese</LastName>
<ForeName>Adriano</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>MCW Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Department of Biochemistry.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kalyanaraman</LastName>
<ForeName>Balaraman</ForeName>
<Initials>B</Initials>
<Identifier Source="ORCID">0000-0002-9180-8296</Identifier>
<AffiliationInfo>
<Affiliation>MCW Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Department of Biophysics.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dwinell</LastName>
<ForeName>Michael B</ForeName>
<Initials>MB</Initials>
<AffiliationInfo>
<Affiliation>From the Department of Microbiology & Immunology, mdwinell@mcw.edu.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>MCW Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Department of Surgery, and.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 CA152810</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 GM067180</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 GM122889</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01 CA178960</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2018</Year>
<Month>08</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Biol Chem</MedlineTA>
<NlmUniqueID>2985121R</NlmUniqueID>
<ISSNLinking>0021-9258</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>8L70Q75FXE</RegistryNumber>
<NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D000071189">Autophagy-Related Protein-1 Homolog</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D000076222">Mechanistic Target of Rapamycin Complex 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C484754">ULK1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.4.3</RegistryNumber>
<NameOfSubstance UI="D000263">Adenylate Kinase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000263" MajorTopicYN="N">Adenylate Kinase</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000071189" MajorTopicYN="N">Autophagy-Related Protein-1 Homolog</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D003110" MajorTopicYN="N">Colonic Neoplasms</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011905" MajorTopicYN="N">Genes, ras</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000076222" MajorTopicYN="N">Mechanistic Target of Rapamycin Complex 1</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D063306" MajorTopicYN="N">Mitophagy</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D010085" MajorTopicYN="N">Oxidative Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="Y">AMP-activated kinase (AMPK)</Keyword>
<Keyword MajorTopicYN="Y">KRAS proto-oncogene</Keyword>
<Keyword MajorTopicYN="Y">cancer biology</Keyword>
<Keyword MajorTopicYN="Y">cell growth</Keyword>
<Keyword MajorTopicYN="Y">cell proliferation</Keyword>
<Keyword MajorTopicYN="Y">colon cancer</Keyword>
<Keyword MajorTopicYN="Y">metformin</Keyword>
<Keyword MajorTopicYN="Y">mitochondrial metabolism</Keyword>
<Keyword MajorTopicYN="Y">mitophagy</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2017</Year>
<Month>12</Month>
<Day>13</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2018</Year>
<Month>07</Month>
<Day>20</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2018</Year>
<Month>8</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2019</Year>
<Month>4</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2018</Year>
<Month>8</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">30087121</ArticleId>
<ArticleId IdType="pii">RA117.001469</ArticleId>
<ArticleId IdType="doi">10.1074/jbc.RA117.001469</ArticleId>
<ArticleId IdType="pmc">PMC6153299</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Cancer Sci. 2008 Nov;99(11):2136-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18803638</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Biochem. 1999 Aug;263(3):709-16</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10469134</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Annu Rev Genet. 2009;43:67-93</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19653858</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Drug Discov. 2014 Nov;13(11):828-51</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25323927</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Lett. 2015 Aug 28;365(1):96-106</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26004344</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>EMBO J. 1995 Nov 1;14(21):5279-87</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7489717</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Opin Cell Biol. 2016 Apr;39:43-52</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26896558</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Free Radic Biol Med. 2011 Nov 1;51(9):1621-35</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21872656</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 1998 Jun 26;273(26):16621-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9632736</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann N Y Acad Sci. 2008 Dec;1147:105-11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19076435</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2010 May 11;107(19):8788-93</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20421486</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochim Biophys Acta. 2012 Sep;1817(9):1597-607</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22627082</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Free Radic Biol Med. 2012 Jan 15;52(2):497-506</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22120494</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Trends Biotechnol. 1997 Aug;15(8):326-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9263481</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Protoc. 2014 Feb;9(2):421-38</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24457333</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Chem Rev. 2017 Aug 9;117(15):10043-10120</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">28654243</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Carcinogenesis. 2005 Jan;26(1):159-67</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15471899</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Cell Biol. 1979 Feb;80(2):248-65</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">88453</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 1982 Sep;79(17):5292-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">6752944</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Pharmacol Exp Ther. 2013 Jan;344(1):167-78</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23086228</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Trends Biochem Sci. 2014 Feb;39(2):91-100</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24388967</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BMC Cancer. 2013 Jun 13;13:285</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23764021</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell. 2008 Apr 25;30(2):214-26</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18439900</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3722-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20133591</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Opin Cell Biol. 2010 Apr;22(2):157-68</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20006481</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 2003 Nov 26;115(5):577-90</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14651849</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Genes Dis. 2016 Mar;3(1):82-87</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">28066797</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Cancer. 2008 Jan 15;122(2):267-73</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17918158</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 1985 Dec;45(12 Pt 1):6093-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">4063967</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diabetes Care. 2011 Oct;34(10):2323-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21949223</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Free Radic Biol Med. 2005 Sep 1;39(5):567-83</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16085176</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Mol Sci. 2015 Jan 23;16(2):2641-62</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25625517</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Physiol Gastrointest Liver Physiol. 2005 Feb;288(2):G316-26</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15358596</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 2002 Jul 26;110(2):177-89</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12150926</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 2006 Aug 17;25(36):4986-97</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16568088</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Semin Cell Dev Biol. 2015 Mar;39:43-55</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25724561</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nutr Rev. 2009 Dec;67(12):677-89</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19941614</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Cell Biol. 2011 Feb;13(2):132-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21258367</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biomacromolecules. 2006 Aug;7(8):2347-56</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16903681</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biophys J. 2009 Feb 18;96(4):1388-98</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19217856</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cold Spring Harb Perspect Biol. 2012 Sep 01;4(9):a011189</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22952397</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS One. 2010 Oct 04;5(10):null</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20957228</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biotechniques. 2011 Feb;50(2):98-115</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21486251</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2012 May 15;72(10):2634-44</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22431711</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 2012 Apr 27;149(3):656-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22541435</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Oncol. 2010 Aug;11(8):753-62</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20619739</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Mol Cell Biol. 2011 Jan;12(1):9-14</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21179058</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Carcinog. 2010 Jul;49(7):662-71</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20564343</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Trends Endocrinol Metab. 2014 Jul;25(7):364-73</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24856037</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Biol. 2012 Jan;32(1):2-11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22025673</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 2012 Apr 13;149(2):274-93</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22500797</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Br J Cancer. 2014 Jul 8;111(1):85-93</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24867695</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 2013 Apr;98(4):1529-40</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23509102</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 2012 Jun 28;486(7404):532-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22722830</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2016 Jul 1;76(13):3904-15</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">27216187</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 2017 Sep 8;292(36):15070-15079</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">28739874</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>EMBO J. 2015 Apr 1;34(7):856-80</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25712477</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Carcinogenesis. 2007 May;28(5):1021-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17148506</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5407-12</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12697897</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Anticancer Drugs. 2013 Oct;24(9):881-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23872912</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell. 2015 Feb 5;57(3):537-51</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25658205</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>World J Gastrointest Oncol. 2015 Nov 15;7(11):271-84</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26600927</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>FEBS Lett. 1997 Jun 23;410(1):78-82</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9247127</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 2002 Jul 26;110(2):163-75</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12150925</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Metab. 2005 Jan;1(1):15-25</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16054041</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Exp Cell Res. 1999 Nov 25;253(1):100-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10579915</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5422-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23513224</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Free Radic Biol Med. 2011 Jun 1;50(11):1546-55</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21402148</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Cell Physiol. 2013 Apr;228(4):835-45</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23018647</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell. 2015 Feb 5;57(3):521-36</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25658204</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 2010 Nov 5;285(45):34447-59</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20805228</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 2001 Feb 16;276(7):4588-96</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11092892</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BMC Cancer. 2012 Mar 26;12:118</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22443173</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Adv Drug Deliv Rev. 2001 Jul 2;49(1-2):63-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11377803</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>Wisconsin</li>
</region>
</list>
<tree>
<noCountry>
<name sortKey="Van Wickle, Jonathan" sort="Van Wickle, Jonathan" uniqKey="Van Wickle J" first="Jonathan" last="Van Wickle">Jonathan Van Wickle</name>
</noCountry>
<country name="États-Unis">
<region name="Wisconsin">
<name sortKey="Boyle, Kathleen A" sort="Boyle, Kathleen A" uniqKey="Boyle K" first="Kathleen A" last="Boyle">Kathleen A. Boyle</name>
</region>
<name sortKey="Dwinell, Michael B" sort="Dwinell, Michael B" uniqKey="Dwinell M" first="Michael B" last="Dwinell">Michael B. Dwinell</name>
<name sortKey="Dwinell, Michael B" sort="Dwinell, Michael B" uniqKey="Dwinell M" first="Michael B" last="Dwinell">Michael B. Dwinell</name>
<name sortKey="Hill, R Blake" sort="Hill, R Blake" uniqKey="Hill R" first="R Blake" last="Hill">R Blake Hill</name>
<name sortKey="Kalyanaraman, Balaraman" sort="Kalyanaraman, Balaraman" uniqKey="Kalyanaraman B" first="Balaraman" last="Kalyanaraman">Balaraman Kalyanaraman</name>
<name sortKey="Marchese, Adriano" sort="Marchese, Adriano" uniqKey="Marchese A" first="Adriano" last="Marchese">Adriano Marchese</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000548 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000548 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    RapamycinFungusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:30087121
   |texte=   Mitochondria-targeted drugs stimulate mitophagy and abrogate colon cancer cell proliferation.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:30087121" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a RapamycinFungusV1 

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 21:55:41 2020. Site generation: Thu Nov 19 22:00:39 2020